UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 208

Sortiert nach

Molecular Biomarkers Related to Oral Carcinoma: Clinical Trial Outcome Evaluation in a Literature Review

Disease markers, 2019-01, Vol.2019, p.8040361-11

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations

Disease markers, 2018-01, Vol.2018, p.3810108-7

2018

Link zum Volltext

Verfügbarkeit prüfen

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials

Scientific reports, 2021-03, Vol.11 (1), p.6637-6637, Article 6637

2021

Link zum Volltext

Verfügbarkeit prüfen

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy

Pharmacology & therapeutics (Oxford), 2018-01, Vol.181, p.156-168

2018

Link zum Volltext

Verfügbarkeit prüfen

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2021-05, Vol.81 (9), p.2566-2573

2021

Link zum Volltext

Verfügbarkeit prüfen

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2738-2745

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Clinical cancer research, 2020-08, Vol.26 (15), p.4135-4142

2020

Link zum Volltext

Verfügbarkeit prüfen

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (12), p.1761-1769

2021

Link zum Volltext

Verfügbarkeit prüfen

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

European journal of cancer (1990), 2020-03, Vol.128, p.17-26

2020

Link zum Volltext

Verfügbarkeit prüfen

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.57-57, Article 57

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1177-1187

2020

Link zum Volltext

Verfügbarkeit prüfen

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001504

2021

Link zum Volltext

Verfügbarkeit prüfen

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e000678

2020

Link zum Volltext

Verfügbarkeit prüfen

Association between immune-related adverse event timing and treatment outcomes

Oncoimmunology, 2022-12, Vol.11 (1), p.2017162-2017162

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

Medical oncology (Northwood, London, England), 2017-06, Vol.34 (6), p.105-105, Article 105

2017

Link zum Volltext

Verfügbarkeit prüfen

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Therapeutic Advances in Respiratory Disease, 2018-01, Vol.12, p.1753466618808659-1753466618808659

2018

Link zum Volltext

Verfügbarkeit prüfen

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

Drugs in context, 2023, Vol.12

2023

Link zum Volltext

Verfügbarkeit prüfen

Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications

Cancers, 2023-01, Vol.15 (3), p.649

2023

Link zum Volltext

Verfügbarkeit prüfen

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.87-87, Article 87

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature communications, 2023-07, Vol.14 (1), p.4238-4238, Article 4238

2023

Link zum Volltext

Verfügbarkeit prüfen

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.e145-e147

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

Translational lung cancer research, 2021-04, Vol.10 (4), p.1857-1872

2021

Link zum Volltext

Verfügbarkeit prüfen

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003536

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(188)

Publikationsform

Artikel
(204)
Berichte
(4)

Sprache

Englisch
(208)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(113)
Life Sciences & Biomedicine
(111)
Oncology
(92)
Humans
(73)
Lung Neoplasms - Drug Therapy
(42)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(39)
Immunotherapy
(38)
Lung Cancer
(35)
Mutation
(32)
Lung Neoplasms - Pathology
(30)
Female
(29)
Lung Neoplasms - Genetics
(28)
Carcinoma, Non-Small-Cell Lung - Genetics
(27)
Male
(27)
Respiratory System
(27)
Cancer
(26)
Aged
(25)
Carcinoma, Non-Small-Cell Lung - Pathology
(25)
Middle Aged
(21)
Tumors
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Molecular Biomarkers Related to Oral Carcinoma: Clinical Trial Outcome Evaluation in a Literature Review

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials

Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Association between immune-related adverse event timing and treatment outcomes

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

Suchergebnisse filtern